Companies /Healthcare

Belite Bio Inc

NASDAQ: BLTE Biotechnology
$171.09
▲ $10.43 (+6.49%) today
Markets closed · 8:17am ET
Today · % change

Fundamentals

Market Cap
$6.5B
EPS (TTM)
$-2.74
52-Week Range
$65 – $200
Street Target
$214.00

About Belite Bio

Belite Bio Inc is a biopharmaceutical company focused on developing treatments for eye diseases and liver conditions. With a leading product, LBS-008 (Tinlarebant), aimed at improving retinal health in patients with specific macular degeneration and Stargardt disease, they are at the forefront of oral therapies in this area. Additionally, they are working on LBS-009 for liver diseases, including fatty liver and type 2 diabetes. Founded in 2016 and based in San Diego, California, Belite Bio is pioneering in its field.

BLTE Coverage